Norinchukin Bank The Has $8.79 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Norinchukin Bank The raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,899 shares of the medical research company’s stock after buying an additional 1,338 shares during the quarter. Norinchukin Bank The’s holdings in Thermo Fisher Scientific were worth $8,791,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Ossiam boosted its holdings in shares of Thermo Fisher Scientific by 22.7% in the 4th quarter. Ossiam now owns 12,095 shares of the medical research company’s stock valued at $6,292,000 after purchasing an additional 2,236 shares in the last quarter. Bank of Nova Scotia Trust Co. lifted its position in shares of Thermo Fisher Scientific by 3.8% during the 4th quarter. Bank of Nova Scotia Trust Co. now owns 2,521 shares of the medical research company’s stock worth $1,311,000 after buying an additional 93 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its position in Thermo Fisher Scientific by 396.9% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 62,616 shares of the medical research company’s stock valued at $32,575,000 after acquiring an additional 50,015 shares during the last quarter. Beck Mack & Oliver LLC raised its stake in Thermo Fisher Scientific by 45.0% during the fourth quarter. Beck Mack & Oliver LLC now owns 1,945 shares of the medical research company’s stock worth $1,012,000 after acquiring an additional 604 shares in the last quarter. Finally, Capital International Inc. CA boosted its stake in shares of Thermo Fisher Scientific by 8.7% in the 4th quarter. Capital International Inc. CA now owns 46,766 shares of the medical research company’s stock valued at $24,329,000 after purchasing an additional 3,729 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 in the last quarter. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $426.11 on Friday. The stock’s 50 day moving average price is $497.67 and its two-hundred day moving average price is $533.64. The stock has a market capitalization of $160.85 billion, a price-to-earnings ratio of 25.78, a PEG ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a 52-week low of $409.85 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.40%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $680.00 to $580.00 and set an “overweight” rating for the company in a research note on Thursday. Citigroup cut their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Scotiabank increased their target price on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research report on Monday, February 3rd. UBS Group boosted their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Finally, StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $642.67.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.